Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2017 Jul 3;5(8):685–694. doi: 10.1158/2326-6066.CIR-16-0330

Figure 3. Tumor eradication requires an immunotoxin with cytotoxic activity and anti-CTLA-4.

Figure 3

Tumor growth curves of individual mice treated with (A) LMB-100 alone, (B) PBS (thick arrows) and anti-CTLA-4 (thin arrows), (C) Mice treated with 30 μg LMB-100 (thick arrows) and anti-CTLA-4 (thin arrows), (D) 30 μg LMB-100-I (thick arrows) and anti-CTLA-4 (thin arrows). The number of mice in complete remission and total mice per group is shown in parentheses. A, C and D shows pooled data from two repeats experiments. (E) Long-term survival of different treatment groups. Only mice in group C showed a significant increase in survival (P < 0.001).